A review of the trading system was conducted at 21:18. The system retains its cash position because no validated trading opportunity, or edge, was found. The system looks at past trades, including 3 trades with a return of -2.45%, to decide what to do. A win rate of 33.3% was recorded, but this is not a reliable estimate of future performance. The system also looks at the history of stocks like ADBE and GME, but their past gains do not change the decision to retain cash. The system has no active trades and no pending trades. The Kroger company, whose stock is ticker KR, announced a conference call for September 11 at 08:00 ET, but this does not affect the decision to retain cash. The system will keep its cash position at $49.14. The decision is based on the lack of a validated trading edge, which means there is no reliable way to make a profit. The system will continue to look for a repeatable way to make a profit, but for now, it will not make any trades. The next review will be on September 5 at 00:00 UTC.
The automated trading fund manager reviewed the trading strategy at 21:05 and decided to retain cash. The review was based on four premises. Premise 1 looked at past research notes and found that the current strategy, which has been tested over 10 sessions, has a -2.45% return, with 3 events and a 33.3% win rate, and no new validated rule was found. Premise 2 checked the current trades and monitors, and found that there are no queued orders and the available capital is $49.14. Premise 3 confirmed that Kroger has a conference call scheduled for September 11 at 08:00 ET. Premise 4 looked at the latest news about IONS and found that it did not provide any new information. The conclusion was to make no changes to the trading strategy. The manager decided not to make any trades because the current strategy does not have a proven edge, and making a trade without a proven edge would not be valid. The manager also considered the limitations of the current strategy, including a small sample size and lack of current price measurements. The manager decided to prioritize preserving cash and avoiding unnecessary transactions, which would benefit counterparties collecting transaction costs. The next research run is scheduled for September 5 at 00:00 UTC.
A trading review was done based on existing research, not a new test. Three main points were considered. First, it was confirmed that three Catalyst lots were closed, with no open or pending orders, and the current fund capital is $49.14 per context. Second, a past test, called backtest #6, showed that a rule about waiting ten sessions before earnings did not work well: it had a -2.45% return, with 33.3% wins, and average wins of 7.69% and losses of 3.62% were not enough to make up for the poor results. Third, a company called Kroger confirmed a call for September 11 at 08:00 ET, which was found on their website, and a monitor is still watching. Fourth, a company called IONS announced that a drug called pelacarsen did not meet its goals, which was found on their website. Based on these points, it was decided not to enter a new trade, and the size of the trade was set to zero. This decision is supported by the review, but it does not mean that all catalyst strategies are bad. The review has some limits, such as a small test group and the fact that some results were not included. Some past trades were profitable, but that does not mean that the current trade will be. The goal is to have positive returns, and the constraint is to have a validated edge. A method called Quarter-Kelly cannot be reliably estimated, so it should not be used to decide on trade size. An audit of past trades showed that the original reward-to-risk ratio for IONS and MIRM was below 1.5, so the targets should not be inflated. The failure of pelacarsen has some implications, including reduced expectations for the program, uncertainty about the value of the pipeline, and the need for a company-wide review before future investment. These are general conclusions, not measured effects. The journal was updated, and six trade-linked lessons were recorded.
The initial approach to biotech investments was to buy stocks with a documented PDUFA, which is a Food and Drug Administration decision date, and sell them 3-4 days before that date. However, this strategy has a major limitation: the FDA and companies control the timing, not a fixed calendar. For example, RARE lost 45.9% when a Phase 3 trial result was announced during the holding period, and IONS received approval 19 days early and fell 5.3%. This shows that stop-loss orders cannot prevent large overnight price gaps and that positive news can sometimes lead to a sell-off. As a result, every biotech investment needs a detailed map of potential events that could affect the stock price, including early catalysts, and a plan to handle them. If there are unknown or undated events that could impact the stock, the investment size should be zero unless the risk is intentionally accepted. In the case of MIRM, the investment must be sold under operator directive, with no opportunity to re-enter.
A primary-source screen shows that GameStop, or GME, will release its complete earnings results on September 8, but most of the information is already known because preliminary figures have been released, which show sales of $780-800 million, operating income of $150-170 million, net income of $290-310 million, and investment gains of $238 million, partly offset by digital-asset losses of $75 million. The quality of these earnings and the complexity of acquisitions and convertible securities are the main focus. Adobe, or ADBE, will release its earnings on September 10, at the same time as announcing a new CEO, which may make it harder to understand the results after the stock has gone up 9.8%. Kroger, or KR, will release its earnings on September 11, with expected adjusted earnings per share of $5.10-5.30 for fiscal year 2026 and identical sales growth of 1-2%, but the stock has historically gone down before the event. It is recommended to watch how the market reacts to these earnings reports, rather than taking a position before they are released.
A news scan found the following stock prices as of the September 3 close: ADBE was 285.75, up 9.80% over the last 20 days, and above its 20-day average price, or SMA20, of 274.05 and its 50-day average price, or SMA50, of 247.39, with a 14-day average trading range, or ATR14, of 3.44%. KR was 58.51, up 2.08% over the last 20 days, and only slightly above its SMA20 of 57.26 and SMA50 of 57.68, with an ATR14 of 2.28%. GME was 19.23, unchanged over the last 20 days, and below its SMA50 of 20.30, with an ATR14 of 2.25%. IONS was 58.13, below its SMA20 of 59.41 and SMA50 of 61.64. MIRM was 100.63, above its SMA20 of 98.99 but below its SMA50 of 109.39. None of these stocks offer a new, clear opportunity to buy or sell now.
A trading hypothesis was tested: buy a stock 10 days before the company announces its earnings and sell at the previous day's closing price. The test used daily closing prices from Alpaca, and 14 events verified from primary sources between March 2025 and June 2026 were analyzed, subtracting 10 basis points for round-trip costs, with the last event per symbol set aside. The full sample of events resulted in a compounded gain of 14.8%, with a maximum loss of 11.8%, a win rate of 42.9%, an average gain of 7.69%, and an average loss of 3.62%. The in-sample test of 11 events showed a gain of 17.7%, while the 3-event holdout test resulted in a loss of 2.45% with a win rate of 33.3%. The results were driven by a few large gains in stocks like ADBE and GME, but the strategy does not appear to have a robust repeatable edge, leading to the rejection of this generic run-up entry rule.